Subclinical visual impairment in phenylketonuria. A neurophysiological study (VEP-P) with clinical, biochemical, and neuroradiological (MRI) correlations

Journal of Inherited Metabolic Disease

Volumn 21, Issue 4, 1998, Pages 351-364

  Leuzzi, V ^a,e   Rinalduzzi, S ^b   Chiarotti, F ^c   Garzia, P ^a   Trasimeni, G ^d   Accornero, N ^b  

^a Servizio Neurosonologia Dip Scienze Neurologiche   (Italy)

^b Dipartimento di Scienze Neurologiche   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e Ist di Neuropsichiatria Infantile   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PHENYLALANINE;

ADOLESCENT; ADULT; ARTICLE; BIOCHEMISTRY; CLINICAL ARTICLE; CLINICAL FEATURE; CONCENTRATION RESPONSE; DIET THERAPY; EVOKED VISUAL RESPONSE; FEMALE; HUMAN; LATENT PERIOD; MALE; NEUROPHYSIOLOGY; NEWBORN SCREENING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENYLKETONURIA; SCHOOL CHILD; VISION; VISUAL IMPAIRMENT;

ADOLESCENT; ADULT; CHILD; EVOKED POTENTIALS, VISUAL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PHENYLALANINE; PHENYLKETONURIAS; REACTION TIME; VISION DISORDERS;

EID: 0031869897     PISSN: 01418955     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005346422918     Document Type: Article

References (45)

1. Barbato L, Rinalduzzi S, Laurenti M, Ruggieri S, Accornero N (1994) Color VEPs in Parkinson's disease. Electroencephalogr Clin Neurophysiol 92: 169-172.
2. Bhaskar PA, Vanchilingam S, Bhaskar EA, Devaprabhu A, Ganesan RA (1986) Effect of L-dopa on visual evoked potential in patients with Parkinson's disease. Neurology 36: 1119-1121.
3. Bick U, Fahrendorf G, Ludolph AC, Vasallo P, Weglage J, Ullrich K (1991) Disturbed myelination in patients with treated hyperphenylalaninaemias: evaluation with magnetic resonance imaging. Eur J Pediatr 150: 185-189.
4. Bodis-Wollner I (1990) Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients. TINS 13: 296-302.
5. Bodis-Wollner I, Yahr M (1982) Measurements of visual evoked potentials in Parkinson's disease. Arch Neurol 39: 284-286.
6. Bodis-Wollner I, Yard MD, Mylin L, Thornton J (1982) Dopaminergic deficiency and delayed visual evoked potentials in humans. Ann Neurol 11: 478-483.
7. Bodis-Wollner I, Marx MS, Mitra S, Bobak P, Mylin L, Yahr M (1987) Visual dysfunction in Parkinson's disease. Loss in spatiotemporal contrast sensitivity. Brain 110: 1675-1698.
8. Bulens C, Meerwaldt JD, van der Wildt GJ, Keemink CJ (1986) Contrast sensitivity in Parkinson's disease. Neurology 36: 1121-1125.
9. Bulens C, Meerwaldt JD, Van der Wildt GJ, Van Deursen BP (1987) Effect of Levodopa treatment on contrast sensitivity in Parkinson's disease. Ann Neurol 22: 365-369.
10. Cardona F, Leuzzi V, Antonozzi I, Benedetti P, Loizzo A (1991) The development of auditory and visual evoked potentials in early treated phenylketonuric children. Electroencephalogr Clin Neurophysiol 80: 8-15.
11. Cardona F, Leuzzi V (1994) The maturation of BAEPs and F-VEP in early treated PKU children. VI International Congress of Inborn Errors of Metabolism, Milano, May 27-31.
12. Cleary MA, Walter JH, Wraith JE, et al (1994) Magnetic resonance imaging of the brain in phenylketonuria. Lancet 344: 87-90.
13. Cosi V, Romani A, Callieco R, Zerbi F (1989) Acute effect of levodopa plus carbidopa on evoked potentials in Parkinson's disease. Boll Soc It Biol Sper 60: 603-609.
14. De Giorgis GF, Nonnis E, Corioni F, et al (1996) Evolution of daytime quiet sleep components in early treated phenylketonuric infants. Brain Dev 18: 201-206.
15. Diamond A (1994) Phenylalanine levels of 6-10mg/d1 may not be as benign as once thought. Acta Paediatr Suppl 407: 89-91.
16. Diamond A, Herzberg C (1996) Impaired sensitivity to visual contrast in children treated early and continuously for phenylketonuria. Brain 119: 523-538.
17. Domenici L, Trimarchi C, Piccolino M, Fiorentini A, Maffei L (1985) Dopaminergic drugs improve human visual contrast sensitivity. Hum Neurobiol 4: 195-197.
18. Ehinger B (1983) Functional role of dopamine in the retina. Prog Retinal Res 2: 213-232.
19. Giovannini M, Valsasina R, Villani R, et al (1988) Pattern reversal visual evoked potentials in phenylketonuria. J Inher Metab Dis 11: 416-421.
20. Hutton JT, Morris JL, Elas JW, Varma R, Poston JN (1991) Spatial contrast sensitivity is reduced in bilateral Parkinson's disease. Neurology 41: 1200-1202.
21. Jones SJ, Turano G, Kriss A, Shawkat F, Kendall B, Thompson AJ (1995) Visual evoked potentials in phenylketonuria: association with brain MRI, dietary state, and IQ. J Neurol Neurosurg Psychiatry 59: 260-265.
22. Knox WE (1972) Phenylketonuria. In Stambury JB, Wyngaarden JB, Fredrickson DS, eds. The Metabolic Basis of Inherited Disease, 3rd Edn. New York: McGraw-Hill, 266-295.
23. Korinthenberg R, Ullrich K, Fullenkemper F (1988) Evoked potentials and electroencephalography in adolescents with phenylketonuria. Neuropediatrics 19: 175-178.
24. Kupersmith MJ, Shakin E, Siegel IM, Lieberman A (1982) Visual system abnormalities in patients with Parkinson's disease. Arch Neurol 39: 284-286.
25. Leuzzi V, Gualdi GF, Fabbrizi F, Trasimeni G, Di Biasi C, Antonozzi I (1993) Neuroradiological (MRI) abnormalities in phenylketonuric subjects: clinical and biochemical correlations. Neuropediatrics 24: 302-306.
26. Leuzzi V, Cardona F, Antonozzi I, Loizzo A (1994) Visual, auditory, and somatosensorial evoked potentials in early and late treated adolescent with phenylketonuria. J Clin Neurophysiol 11: 602-606.
27. Leuzzi V, Trasimeni G, Gualdi GF, Antonozzi I (1995) Biochemical, clinical and neuroradiological (MRI) correlations in late detected PKU patients. J Inher Metab Dis 5: 624-634.
28. Lou HC, Toft PB, Andresen J, et al (1992) An occipito-temporal syndrome in adolescent with optimally controlled hyperphenylalaninaemia. J Inher Metab Dis 15: 687-695.
29. Ludolph AC, Ullrich K, Nedjat S, Masur H, Bick U (1992) Neurological outcome in 22 treated adolescents with hyperphenylalaninemia. A clinical and electrophysiological study. Acta Neurol Scand 85: 243-248.
30. Ludolph AC, Vetter U, Ullrich K (1996) Studies of multimodal evoked potentials in treated phenylketonuria: the pattern of vulnerability. Eur J Pediatr 155(supplement 1): S64-S68.
31. Onofrj M, Ghilardi MF, Basciani M, Gambi D (1986) Visual evoked potential in parkinsonism and dopamine blockade reveals stimulus dependent functions in humans. J Neurol Neurosurg Psychiatry 49: 1150-1159.
32. Pearsen KD, Gean-Marton AD, Levy HL, Davis KR (1990) Phenylketonuria: MR imaging of the brain with clinical correlation. Radiology 177: 437-440.
33. Piccolino M (1986) Horizontal cells of the retina: historical controversies and new interest. Prog Retinal Res 5: 147-163.
34. Price MJ, Feldman RG, Adelberg D, Kayane H (1992) Abnormalities in color vision and contrast senstivity in Parkinson's disease. Neurology 42: 887-890.
35. Scriver CR, Kaufman S, Eisensmith RC, Woo SLC (1995) The hyperphenylalaninemias. In Scriver RC, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, 7th edn. New York: McGraw-Hill, 1015-1075.
36. Shaw DWW, Maravilla KR, Weinberger E, Garretson J, Trahms CM, Scott CR (1991) MR Imaging of phenylketonuria. AJNR 12: 403-406.
37. Skrandies W, Gottlob I (1986) Alterations of visual contrast sensitivity in Parkinson's disease. Hum Neurobiol 5: 255-259.
38. Smith I, Wolff OH (1974) Natural history of phenylketonuria and influence of early treatment. Lancet 2: 540-544.
39. Sollazzo D (1985) Influence of L-dopa/carbidopa on pattern reversal VEP: behavioural differences in primary and secondary parkinsonism. Electroencephalogr Clin Neurophysiol 61: 236-242.
40. Tartaglione A, Pizio N, Bino G, Spadavecchia L, Favale E (1984) VEP changes in Parkinson's disease are stimulus specific. J Neurol Neurosurg Psychiatry 47: 305-307.
41. Thompson AJ, Smith I, Kendall BE, Youl BD, Brenton D (1991) Magnetic resonance imaging changes in early treated patients with phenylketonuria. Lancet 337: 1224 (Letter).
42. Thompson AJ, Tillotson S, Smith I, Kendall B, Moore SG, Brenton DP (1993) Brain MRI changes in phenylketonuria. Association with dietary status. Brain 116: 811-821.
43. Ullrich K, Weglage J, Oberwittler C, et al (1994) Effect of L-DOPA on pattern visual evoked potentials (P-100) and neuropsychological tests in untreated adult patients with phenylketonuria. J Inher Metab Dis 17: 349-352.
44. Weglage J, Möller H, Wiedermann D, Cipcic-Schmidt S, Zsocke J, Ullrich K (1998) In vivo NMR spectroscopy in patients with phenylketonuria: clinical significance of interindividual differences in brain phenylalanine concentrations. J Inher Metab Dis 21: 81-82.
45. Woolf LI (1979) Late onset phenylalanine intoxication. J Inher Metab Dis 2: 19-20.